New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMGF (Mechano Growth Factor) vs Cagrilintide

MGF (Mechano Growth Factor) vs Cagrilintide

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
MGF (Mechano Growth Factor)
GLP-1 / Weight Loss Agonists
Cagrilintide
Summary
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Half-Life
Native MGF: minutes. PEG-MGF: ~3 days
~7–10 days
Admin Route
SubQ, IM
SubQ
Research
Typical Dose
200–400 mcg
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
Frequency
1–2 times per week
Once weekly
Key Benefits
  • Activates muscle satellite cells for repair and growth
  • Accelerates recovery from muscle damage
  • Synergistic with IGF-1 LR3 (different mechanisms)
  • Promotes muscle hypertrophy specifically at exercised muscles
  • Faster recovery between training sessions
  • Potential for injury repair in connective tissue
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
Side Effects
  • Muscle soreness (satellite cell activation)
  • Injection site irritation
  • Hypoglycemia risk (modest, less than IGF-1 LR3)
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
Stacks With